市場調查報告書
商品編碼
1401018
生物電醫學全球市場規模、佔有率、產業趨勢分析報告:2023-2030 年按類型、最終用途、產品、應用、地區分類的展望與預測Global Bioelectric Medicine Market Size, Share & Industry Trends Analysis Report By Type, By End-use, By Product, By Application, By Regional Outlook and Forecast, 2023 - 2030 |
2030年,生物電醫藥市場規模預計將達317億美元,預測期內市場成長率為6.1%。
根據 KBV Cardinal 矩陣中發布的分析,雅培實驗室 (Abbott Laboratories) 和美敦力 (Medtronic PLC) 是市場推動者。 2021 年 11 月,美敦力 (Medtronic) PLC 與 Rune Labs 合作,該公司利用集中的大腦資料來推動神經和精神疾病精準藥物的開發和交付。該合作夥伴關係旨在評估 BrainSense 技術的使用,這是第一個也是唯一一個能夠長期捕獲和記錄腦波訊號的完整深部腦部刺激系統。 Boston Scientific Corporation、Nevro Corporation 和 electroCore, Inc. 等公司是該市場的主要創新者。
COVID-19 影響分析
疫情擾亂了全球供應鏈,影響了生物電設備和零件的生產和分銷。封鎖、旅行限制和勞動力挑戰導致製造和供應延遲,影響了某些生物電技術的可得性。由於實驗室暫時關閉且資源被重新分配到與 COVID-19 相關的研究,市場上的許多研發活動都被推遲。新生物電療法的臨床試驗面臨中斷,影響了產品開發進度。因此,COVID-19的爆發對市場產生了負面影響。
市場成長要素
世界高齡化人口增加
老齡化過程與心血管疾病、神經神經退化性疾病(如阿茲海默症和帕金森氏症)、關節炎和其他與老齡化相關的疾病等慢性疾病的風險增加有關。生物電介入可以透過其調節生理過程的潛力提供有效管理和治療這些疾病的新方法。生物電醫學的目的不僅是治療疾病,還旨在提高整體生活品質。生物電干預,包括神經調節和其他技術,可以改善這些方面並促進老年人生活品質的提高。預計這些因素將有助於市場擴張。
加大研發投入
對研究的投資可以幫助找到核准和商業化的監管途徑。滿足監管標準對於將生物電療法推向市場至關重要,持續的投資將支持滿足這些要求所需的研究和記錄。產業領導者的資源投入將有助於擴大市場。隨著新治療方法的開發並被證明有效,它們可以覆蓋更廣泛的患者群體並提高市場滲透率。因此,這些因素預計將為市場提供良好的成長前景。
市場抑制因素
藥品核准相關問題
尋求在國際上銷售產品的生物電公司面臨著適應多種法律規範的挑戰。地區之間核准流程和要求的差異可能會增加整體監管時間表的複雜性和長度。監管機構可能面臨調整現有框架以適應快速發展的生物電子醫學技術的挑戰。由於某些生物電療法的新穎性和獨特性,監管機構可能需要製定專門的指南。這些因素將阻礙市場的成長。
按類型分類的展望
按類型分類,市場可分為植入式電療設備和非侵入性電療設備。到2022年,非侵入性電療設備領域將佔據市場主要收益佔有率。非侵入性電療設備為侵入性手術提供了對患者友善的替代方案。患者通常喜歡非侵入性治療,因為這種治療可以減少疼痛、最小程度的不適並且無需手術干預。這種方法提高了患者的依從性並有助於營造積極的患者體驗。技術進步對於開發先進的非侵入性電療設備至關重要。經皮電刺激和非侵入性神經調節等創新技術正在擴大非侵入性干預的範圍。因此,該領域很可能在未來幾年內迅速擴張。
最終用途展望
根據最終用途,市場分為醫院和其他。 2022 年,醫院細分市場收益佔有率最大。生物電干預正在廣泛應用於各種醫學專業,從神經病學和疼痛管理到心臟病學和復健。生物電療法的多功能性使其能夠治療多種醫療狀況,促使醫院在各個部門探索和實施這些干預措施。因此,這些因素推動了醫院領域的成長。
產品展望
產品分為植入式心臟整流去顫器/心臟節律器、人工電子耳耳蝸、脊髓刺激設備、深層腦部刺激器、經皮電神經刺激設備、薦/迷走神經刺激設備等。 2022 年,脊髓刺激設備領域在市場中獲得了可觀的收益佔有率。脊髓刺激設備通常用作治療慢性疼痛的選擇,例如腰部手術失敗綜合症和複雜性局部疼痛症候群。這些疾病的盛行率不斷上升,加上人口高齡化,可能會導致脊髓刺激設備的需求增加。因此,該領域很可能在未來幾年內迅速擴張。
按用途分類的展望
依應用,市場分為心律不整、疼痛管理、感感音性聽障、巴金森氏症、震顫/癲癇、憂鬱症、抗治療性憂鬱症、尿液/大便失禁等。 2022年,震顫/癲癇細分市場在市場中佔據很大的收益佔有率。震顫和癲癇常伴隨腦部異常電活動。神經調節療法是生物電醫學的關鍵組成部分,利用電刺激來調節神經活動。神經調節技術的進步可能為震顫和癲癇等疾病帶來更有效的治療方法。由於這些因素,該領域預計將迅速擴大。
區域展望
從區域來看,市場分為北美、歐洲、亞太地區和拉丁美洲地區。 2022 年,北美市場的收益佔有率最高。北美特別是美國在醫療保健產業中發揮重要作用,擁有強大的醫療技術和創新產業。該地區處於生物電醫學研究和開發的前沿。與學術機構、研究中心和產業的合作促進創新,並常常導致新生物電療法和設備的開發。因此,預計該細分市場在未來幾年將會成長。
The Global Bioelectric Medicine Market size is expected to reach $31.7 billion by 2030, rising at a market growth of 6.1% CAGR during the forecast period.
Deep brain stimulation (DBS) is a well-established technique involving implanted electrodes to deliver electrical impulses to specific brain regions, providing therapeutic benefits in conditions like Parkinson's disease. Therefore, Deep Brain Stimulators segment generated $1,022.1 million revenue in the market in 2022. Likewise, neuromodulation techniques, such as transcranial magnetic stimulation (TMS), and deep brain stimulation, are being explored for their potential in various neurological and psychiatric disorders. These techniques aim to modulate neural activity to restore normal functioning and alleviate symptoms. These aspects will lead to increased demand in the market.
The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In August, 2021, electroCore, Inc. signed an agreement with Red One Medical Devices, LLC, a service-disabled veteran-owned small business. This agreement aimed to widen the availability of electroCore's gammaCore platform in the federal marketplace. Moreover, In May, 2020, Medtronic collaborated with UW following which the company has accelerated research into deep brain stimulation treatment for essential tremor, Parkinson's disease, and other neurological disorders.
Based on the Analysis presented in the KBV Cardinal matrix; Abbott Laboratories and Medtronic PLC are the forerunners in the Market. In November, 2021, Medtronic PLC partnered with Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases. This partnership aimed to assess the use of BrainSense technology, the first and only complete Deep Brain Stimulation system able to chronically capture and record brain signals. Companies such as Boston Scientific Corporation, Nevro Corporation and electroCore, Inc. are some of the key innovators in the Market.
COVID-19 Impact Analysis
The pandemic disrupted global supply chains, affecting the production and distribution of bioelectric devices and components. Lockdowns, travel restrictions, and workforce challenges led to delays in manufacturing and supply, impacting the availability of certain bioelectric technologies. Many research and development activities in the market experienced delays as laboratories were temporarily closed, and resources were redirected toward COVID-19-related research. Clinical trials for new bioelectric therapies faced interruptions, affecting timelines for product development. Therefore, the COVID-19 pandemic led to a negative impact on the market.
Market Growth Factors
Growing aging population globally
The aging process is associated with an increased risk of chronic diseases such as cardiovascular disorders, neurodegenerative conditions (like Alzheimer's and Parkinson's diseases), arthritis, and other age-related ailments. Bioelectric interventions, through their potential to modulate physiological processes, can offer novel approaches to manage and treat these conditions effectively. Bioelectric medicine aims not only to treat diseases but also to enhance the overall quality of life. Bioelectric interventions, including neuromodulation and other techniques, can improve these aspects and promote a better quality of life for elderly individuals. These factors will help in the expansion of the market.
Rising investments in research and development
Investment in research helps navigate regulatory pathways for approval and commercialization. Meeting regulatory standards is crucial for bringing bioelectric therapies to the market, and ongoing investment supports the necessary studies and documentation to meet these requirements. The commitment of resources from industry leaders contributes to expanding the market. As new therapies are developed and proven effective, they can reach a broader patient population, increasing market penetration. Therefore, these factors will pose lucrative growth prospects for the market.
Market Restraining Factors
Challenges related to regulatory approval
Bioelectric companies looking to market their products internationally face the challenge of navigating multiple regulatory frameworks. Differences in approval processes and requirements across regions can add complexity and length to the overall regulatory timeline. Regulatory agencies may face challenges in adapting existing frameworks to accommodate rapidly evolving technologies in bioelectric medicine. The novelty and uniqueness of some bioelectric therapies may require regulatory agencies to develop specialized guidelines. These elements will hamper the growth of the market.
Type Outlook
By type, the market is bifurcated into implantable electroceutical devices and non-invasive electroceutical devices. In 2022, the non-invasive electroceutical devices segment witnessed a substantial revenue share in the market. Non-invasive electroceutical devices provide a patient-friendly alternative to invasive procedures. Patients often prefer non-invasive treatments due to reduced pain, minimal discomfort, and the absence of surgical interventions. This approach enhances patient compliance and contributes to a positive patient experience. Technological advancements have been crucial in developing sophisticated, non-invasive electroceutical devices. Innovative technologies, such as transdermal electrical stimulation and non-invasive neuromodulation, have expanded the scope of non-invasive interventions. Therefore, the segment will expand rapidly in the upcoming years.
End-use Outlook
On the basis of end-use, the market is divided into hospitals and others. The hospitals segment recorded the maximum revenue share in the market in 2022. Bioelectric interventions are finding applications across various medical specialties, ranging from neurology and pain management to cardiology and rehabilitation. The versatility of bioelectric therapies makes them relevant for addressing diverse medical conditions, prompting hospitals to explore and implement these interventions within various departments. Thus, these factors will fuel the growth of the hospitals segment.
Product Outlook
Based on product, the market is segmented into implantable cardioverter defibrillators & cardiac pacemakers, cochlear implants, spinal cord stimulators, deep brain stimulators, transcutaneous electrical nerve stimulators, sacral & vagus nerve stimulators, and others. In 2022, the spinal cord stimulators segment garnered a significant revenue share in the market. Spinal cord stimulators are often used as a therapeutic option for managing chronic pain conditions, such as failed back surgery syndrome and complex regional pain syndrome. The rising prevalence of these conditions, coupled with a growing aging population, can contribute to an increased demand for spinal cord stimulators. Therefore, the segment will expand rapidly in the coming years.
Application Outlook
Based on application, the market is divided into arrhythmia, pain management, sensorineural hearing loss, Parkinson's disease, tremor & epilepsy, depression, treatment-resistant depression, urinary & fecal incontinence, and others. In 2022, the tremor and epilepsy segment witnessed a substantial revenue share in the market. Tremors and epilepsy often involve abnormal electrical activity in the brain. Neuromodulation therapies, a significant component of bioelectric medicine, involve the use of electrical stimulation to modulate neural activity. Advances in neuromodulation technologies may lead to more effective treatments for conditions such as tremors and epilepsy. These factors will lead to rapid expansion of the segment.
Regional Outlook
By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America, particularly the United States, has been a significant player in the healthcare industry, with a robust industry for medical technologies and innovations. The region has been at the forefront of bioelectric medicine research and development. Academic institutions, research centers, and industry collaborations often drive innovation, leading to the development of novel bioelectric therapies and devices. Thus, the segment will witness increased growth in the coming years.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, Cochlear Ltd., LivaNova PLC, Koninklijke Philips N.V., Biotronik SE & Co. KG, Sonova Holding AG, Nevro Corporation, and electroCore, Inc.
Recent Strategies Deployed in Bioelectric Medicine Market
Mergers & Acquisition
May-2022: Medtronic plc acquired Intersect ENT, a medical technology company. This acquisition aimed to increase Medtronic's comprehensive ear, nose, and throat offering with innovative products used in sinus procedures to enhance post-operative outcomes and treat nasal polyps.
Nov-2021: Koninklijke Philips N.V. acquired Cardiology, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology. Through his acquisition, Koninklijke Philips N.V. would be able to strengthen its diagnostics offering and cardiac monitoring with electrocardiogram (ECG) analysis, creative software technology, and reporting services.
Feb-2021: Koninklijke Philips N.V. took over BioTelemetry, Inc., a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Koninklijke Philips N.V. would be in a favourable position to enhance patient care across care environments for medical conditions and numerous diseases with the help of the combination of both the organization's portfolio and service platforms.
Jan-2020: Medtronic took over Stimgenics, a startup company that has developed a novel spinal cord stimulation waveform. This acquisition enabled the company to expand its business in the SCS Market.
Jun-2019: Boston Scientific acquired Vertiflex, a healthcare company. Through this acquisition, Vertiflex's spinal cord stimulation and radiofrequency ablation have been added to Boston Scientific's product portfolio.
Partnerships, Collaborations & Agreements
Nov-2021: Medtronic PLC partnered with Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases. This partnership aimed to assess the use of BrainSense technology, the first and only complete Deep Brain Stimulation system able to chronically capture and record brain signals.
Aug-2021: electroCore, Inc. signed an agreement with Red One Medical Devices, LLC, a service-disabled veteran-owned small business. This agreement aimed to widen the availability of electroCore's gammaCore platform in the federal marketplace.
May-2020: Medtronic collaborated with UW following which the company has accelerated research into deep brain stimulation treatment for essential tremor, Parkinson's disease, and other neurological disorders.
May-2019: Abbott came into partnership with the US National Institutes of Health (NIH). The partnership was aimed at developing unique insights and driving the application of neurostimulation therapies. The partnership would provide the latter company's neuroscience research initiative BRAIN access to Abbott's neuromodulation technologies.
Product Launches and Product Expansions
Dec-2022: electroCore, Inc. rolled out Truvaga, a new wellness product offering. The launched product aimed to provide a drug-free, simple, and convenient way to support in reducing stress with just 2-minute sessions, day and night; no apps, batteries, chargers, or phones are required.
Nov-2022: electroCore, Inc. introduced gammaCore Sapphire, the first and only FDA-cleared non-invasive device. The launch would be aimed at treating and preventing multiple types of headache pain via the vagus nerve.
Oct-2020: Abbott Laboratories introduced ICD (Implantable Cardioverter-Defibrillator), a medical device that monitors heart rhythms and delivers shocks to treat life-threatening arrhythmias, and CRT-D (Cardiac Resynchronization Therapy with Defibrillation), an ICD with an added feature to synchronize the contractions of the heart's ventricles, improving heart function in certain patients.
Jan-2020: Medtronic announced the CE mark for its Percept PC neurostimulator. This is a Deep Brain Stimulation (DBS) system with BrainSense technology. The system can sense and record brain signals while offering therapy to patients with neurologic disorders, such as Parkinson's disease.
Oct-2019: Medtronic launched Activa Programming, a new system. The system enables the patients in managing their deep brain stimulation (DBS) treatments at home using a dedicated and customized Samsung smartphone.
Jan-2019: Cochlear Ltd. launched Nucleus 7 Sound Processor, implantable hearing device for the people with single-sided deafness, conductive and mixed hearing loss.
Jan-2019: Boston launched WaveWriter Spinal Cord Stimulator (SCS) System in Europe for providing the treatment of chronic pain to people in Europe.
Jan-2019: Boston Scientific introduced the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems. The systems feature the Vercise Cartesia Directional Lead. The systems have the technology that enables the physicians in controlling the range, shape, position, and direction of electrical stimulation to treat the symptoms of Parkinson's disease (PD) through highly-personalized therapy.
Geographical Expansion
Sep-2019: Sonova opened a new training center in Germany. This expansion aimed to provide training program for hearing care professionals.
Mar-2019: Cochlear Ltd. expanded its reach to UK. This expansion aimed to provide the criteria for cochlear implant to professionals.
Approvals and Trials
Jul-2023: Abbott Laboratories got approval from the FDA for the AVEIR dual chamber (DR) leadless pacemaker system, an advanced medical device that offers dual-chamber pacing capabilities without the need for traditional leads or wires, improving patient comfort and reducing potential complications.
Oct-2022: Nevro Corporation got FDA approval for the Senza HFX iQ spinal cord stimulation (SCS) system, the first and only Artificial Intelligence-based SCS system. The approved product would address the variability in pain from patient to patient and support patients to optimize and maintain long-term pain relief and improved quality of life.
Jan-2021: Medtronic plc introduced the first enrollment in ADAPT-PD. This trial aimed to evaluate the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease.
Jan-2020: Abbott Laboratories got approval from the US Food and Drug Administration (FDA) for its Infinity Deep Brain Stimulation (DBS) system. This system would be used in the treatment of Parkinson's disease. The system would enable targeting a specific area of the brain known as the internal globus pallidus (GPi) for improving the symptoms of Parkinson's disease not controlled by medication.
Nov-2019: Nevro Corporation received approval from the FDA for the Senza Omnia Spinal Cord Stimulation (SCS) System. The Omnia system has been designed to deliver Nevro's proprietary HF10 therapy in addition to all other available SCS frequencies.
Market Segments covered in the Report:
By Type
By End-use
By Product
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research